2014 - ESSA Pharma

Skip to content

Our Company
Pipeline
News
Investors
Contact

ESSA PHARMA, INC. HAS BEGUN DEVELOPMENT OF A SECOND GENERATION ANITEN COMPOUND FOR THE TREATMENT OF HORMONE-DRIVEN CANCER

News

News Archives

2020
2019
2018
2017
2016
2015
2014

Date	Title
December 23, 2014	ESSA Pharma Inc. Becomes Reporting Issuer and Receives Conditional Approval to Commence Trading on TSX-V Exchange

Home

Our Company
Executive Team
Board of Directors
Scientific Advisors
Careers

Pipeline
Expanded Access Policy
Androgen Receptor
Aniten Compounds
Publications

News
Press Releases

Investors
Corporate Governance
Events & Presentations
Financial Information
Stock Information
Analyst Coverage
Investor Contact

Contact
Locations & Inquiries

© ESSA Pharma, Inc. 2020. All rights reserved. Privacy Policy | Terms & Conditions | Code of Conduct